Search tips
Search criteria 


Logo of hccpBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleHereditary Cancer in Clinical PracticeJournal Front Page
Hered Cancer Clin Pract. 2010; 8(Suppl 1): P1.
Published online 2010 May 25. doi:  10.1186/1897-4287-8-S1-P1
PMCID: PMC2876281

Colorectal cancer risk in patients with inflammatory bowel disease and Lynch syndrome



Chronic inflammatory bowel disease (IBD) and Lynch syndrome (LS) are associated with an increased risk for developing colorectal cancer (CRC). After 8-10 years of pan-ulcerative colitis (DC), the risk of CRC is 2%, increasing by 0.5-1.0% annually. LS has been associated with a 60-80% lifetime risk of CRC. It is unclear whether individuals diagnosed with both IBD and LS would have a cumulative risk or earlier age of onset of CRC based on their diagnoses.


Patients with IBD and a germline mismatch repair gene (MMR) mutation were identified through the Familial Gastrointestinal Cancer Registry at Mount Sinai Hospital in Toronto, Canada. Information on their IBD diagnosis, colorectal screening/surgery, medication use, family history and genetic test results were collected (Table (Table11).


Five of 329 (1.5%) individuals with germline MMR mutations reported having a history of IBD.


Concurrent IBD and LS did not appear to predispose to early-onset CRC in our small case series.

Articles from Hereditary Cancer in Clinical Practice are provided here courtesy of BioMed Central